Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 24 NOVEMBER 2025

Daniel's Law Legislation

Klein Moynihan Turco LLP
Explore more from Klein Moynihan Turco LLP

Our readers are familiar with a New Jersey State law known as Daniel's Law, and the entity responsible for an influx of lawsuits alleging that companies violated the law.

United StatesCorporate/Commercial Law
David O. Klein
David O. Klein
Author LinkedIn connections

Our readers are familiar with a New Jersey State law known as Daniel's Law, and the entity responsible for an influx of lawsuits alleging that companies violated the law. Recently, a New Jersey State Senator introduced legislation to "eliminate the loopholes and reaffirm the law's original intent." Below, we discuss the Daniel's Law legislation in detail and its implications on the future of Daniel's Law lawsuits.

Daniel's Law Legislation Aims to Fix "Broken" Law

On November 13, 2025, New Jersey State Senator Gordon Johnson ("Sen. Johnson"), a former member of law enforcement, introduced the "Protect Daniel's Law Act." If adopted, the proposed legislation would: (1) restore the New Jersey State Office of Information Privacy ("OIP"), which was eliminated in 2023; (2) require the OIP to create an online portal to make it easier for people covered under Daniel's Law to register and for businesses to comply with the law; (3) eliminate loopholes that allow companies

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP